| Jennifer Allison Ross, MD | |
|
2 Brookline Pl, Brookline, MA 02445-7230 | |
| (617) 355-2727 | |
| Not Available |
| Full Name | Jennifer Allison Ross |
|---|---|
| Gender | Female |
| Speciality | Pediatrics - Medical Toxicology |
| Location | 2 Brookline Pl, Brookline, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104289461 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 288309 (Massachusetts) | Secondary |
| 2080T0002X | Pediatrics - Medical Toxicology | 288309 (Massachusetts) | Primary |
| Entity Name | Children's Hospital Pediatric Associates, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457306664 PECOS PAC ID: 3476541830 Enrollment ID: O20040504000964 |
News Archive
A.P. Pharma, Inc. has announced that it has submitted a New Drug Application (NDA) for its lead product, APF530, to the U.S. Food and Drug Administration (FDA). APF530 is being developed for the prevention of chemotherapy-induced nausea and vomiting (CINV) and is a long-acting formulation of granisetron that utilizes the Company's proprietary Biochronomer drug delivery system.
The market for point of care diagnostics reached $17 billion, in 2014, according to Kalorama Information. The term refers to diagnostic tests performed outside the central laboratory or decentralized.
Researchers know that heavy alcohol intake can lead to structural and functional changes in the brain, but have not been able to establish direct links between these changes and specific cognitive functions.
Mayo Clinic researchers have found a way to detect and eliminate potentially troublemaking stem cells to make stem cell therapy safer. Induced Pluripotent Stem cells, also known as iPS cells, are bioengineered from adult tissues to have properties of embryonic stem cells, which have the unlimited capacity to differentiate and grow into any desired types of cells, such as skin, brain, lung and heart cells.
HemaQuest Pharmaceuticals announced today that it has initiated the Company's Phase 2 clinical trial evaluating its proprietary HQK-1004 therapy for the treatment of lymphomas and related cancers associated with Epstein-Barr virus (EBV) infection. These EBV-related cancers have poor prognoses and short patient survival. Currently available cancer therapies are typically much less effective in patients with EBV-related lymphoid malignancies than in patients who have similar cancers not infected with the virus.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jennifer Allison Ross, MD 300 Longwood Ave, Boston, MA 02115-5724 Ph: () - | Jennifer Allison Ross, MD 2 Brookline Pl, Brookline, MA 02445-7230 Ph: (617) 355-2727 |
News Archive
A.P. Pharma, Inc. has announced that it has submitted a New Drug Application (NDA) for its lead product, APF530, to the U.S. Food and Drug Administration (FDA). APF530 is being developed for the prevention of chemotherapy-induced nausea and vomiting (CINV) and is a long-acting formulation of granisetron that utilizes the Company's proprietary Biochronomer drug delivery system.
The market for point of care diagnostics reached $17 billion, in 2014, according to Kalorama Information. The term refers to diagnostic tests performed outside the central laboratory or decentralized.
Researchers know that heavy alcohol intake can lead to structural and functional changes in the brain, but have not been able to establish direct links between these changes and specific cognitive functions.
Mayo Clinic researchers have found a way to detect and eliminate potentially troublemaking stem cells to make stem cell therapy safer. Induced Pluripotent Stem cells, also known as iPS cells, are bioengineered from adult tissues to have properties of embryonic stem cells, which have the unlimited capacity to differentiate and grow into any desired types of cells, such as skin, brain, lung and heart cells.
HemaQuest Pharmaceuticals announced today that it has initiated the Company's Phase 2 clinical trial evaluating its proprietary HQK-1004 therapy for the treatment of lymphomas and related cancers associated with Epstein-Barr virus (EBV) infection. These EBV-related cancers have poor prognoses and short patient survival. Currently available cancer therapies are typically much less effective in patients with EBV-related lymphoid malignancies than in patients who have similar cancers not infected with the virus.
› Verified 3 days ago
Rebecca A Horne, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1180 Beacon St, Suite 4a, Brookline, MA 02446 Phone: 617-232-2915 | |
Dr. Sari Joan Rotter, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 637 Washington St, Suite 202, Brookline, MA 02446 Phone: 617-232-2811 Fax: 617-277-8180 | |
Mary E Gordon, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: Children's Hospital, 300 Longwood Ave, Brookline, MA 02115 Phone: 617-355-6000 | |
Dr. Bruce Willard Bunnell, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: One Brookline Place, Suite 327 Centre Pediatric Associates Pc, Brookline, MA 02445 Phone: 617-735-8585 Fax: 617-232-0572 | |
Jennifer M Lewis, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 8 Penniman Rd, Brookline, MA 02445 Phone: 617-738-9001 | |
Dr. Lisa Elaine Schnettler, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 28 James St Apt B, Brookline, MA 02446 Phone: 513-314-8052 |